Ann: Change of Director's Interest Notices x2, page-72

➖ DID YOU KNOW?➖

The very first monoclonal antibody was approved by the FDA thirty-five years ago. Today, there are 100 antibodies approved by the FDA, 41 of which have been developed for the treatment of cancers.

Antibodies are fast becoming an attractive treatment option, due to their ability to target different tissues or biochemical processes with precision.

Patrys’ deoxymab antibodies - PAT-DX1 and PAT-DX3 - are being developed to treat hard-to-reach-and-treat cancers, and as far as we know, none of the 100 approved antibodies have the ability to cross the blood brain barrier.

As we move towards the clinic, Patrys’ deoxymabs may prove to be one of the first antibody‑based therapeutics that can be used to treat cancers in the brain.

Now bring on that next ann due within days and before 2022.............even if just to inform us that all is going well